Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TLR9 agonist

DRUG CLASS:

TLR9 agonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	AST-008 Sensitive: B - Late Trials AST-008 Sensitive : B	AST-008 Sensitive: B - Late Trials AST-008 Sensitive : B
No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + CMP-001 Sensitive: B - Late Trials nivolumab + CMP-001 Sensitive : B	nivolumab + CMP-001 Sensitive: B - Late Trials nivolumab + CMP-001 Sensitive : B
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab + CMP-001 Sensitive: B - Late Trials pembrolizumab + CMP-001 Sensitive : B	pembrolizumab + CMP-001 Sensitive: B - Late Trials pembrolizumab + CMP-001 Sensitive : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + DV281 Sensitive: C3 – Early Trials nivolumab + DV281 Sensitive : C3	nivolumab + DV281 Sensitive: C3 – Early Trials nivolumab + DV281 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	pembrolizumab + SD-101 Sensitive: C3 – Early Trials pembrolizumab + SD-101 Sensitive : C3	pembrolizumab + SD-101 Sensitive: C3 – Early Trials pembrolizumab + SD-101 Sensitive : C3
CD8 positive	Melanoma	CD8 positive	Melanoma	nivolumab + CMP-001 Sensitive: C3 – Early Trials nivolumab + CMP-001 Sensitive : C3	nivolumab + CMP-001 Sensitive: C3 – Early Trials nivolumab + CMP-001 Sensitive : C3